ABIVAX Société Anonyme (NASDAQ:ABVX) is one of best emerging tech stocks to invest in. On December 18, Guggenheim analyst Yatin Suneja raised the company’s price target on ABIVAX from $150 to $175, with a buy rating on the shares. This sentiment was expressed as the company cited its optimistic outlook for obefazimod in the 44-week maintenance report, which is currently forthcoming.
On December 15, ABIVAX reported its financial results for the third quarter of 2025. The company generated revenue of $2.40 million, beating Street estimates of $1.06 million. However, there was a loss per share totaling $1.68 during the quarter. The net loss for the nine months widened to 254.1 million euros, compared to 136.9 million euros in 2024 ($297.94 million and $160.52 million, respectively). The company’s financial activity reflects an increased focus on its lead candidate, obefazimod, a first-in-class oral miR-124 activator.
R&D expenses amounted to €133.4 million, driven by the progression of the Phase 3 ABTECT program in ulcerative colitis/UC and the Phase 2b ENHANCE-CD trial in Crohn’s disease. ABIVAX is preparing to achieve several major milestones in 2026. Initial results from the ABTECT maintenance trial are expected in the second quarter of 2026, which will serve as the final clinical basis for an anticipated NDA submission to the FDA in the second half of this year.
ABIVAX Société Anonyme (NASDAQ: ABVX) is a clinical-stage biotechnology company developing therapeutic products that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases.
While we recognize ABVX’s potential as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for a hugely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the reshoring trend, check out our free report on the best AI stock in the short term.
READ NEXT: 30 stocks that should double in 3 years And 11 Hidden AI Stocks to Buy Right Now.
Disclosure: None. This article was originally published on Initiated Monkey.
